This is a prospective, multicenter, observational study of Chinese pediatric NF1-PN patients treated with selumetinib. The study will be conducted at approximately 12 centers in China and will include approximately 80-100 patients. Treatment centers that have PN diagnosis and/or selumetinib treatment experience will be targeted for recruitment. Patients/caregivers who are eligible and willing to participate will be enrolled into the study. Patients will start selumetinib treatment after enrollment. The study will have a 16-month enrollment period. Patients will be followed up until the end of a 24-month observation period after first dose of selumetinib, or patient death, lost to follow-up, withdrawal of consent, whichever occurs first. Patients will be followed within a 24-month period (starting after first dose received) in the study even if selumetinib is discontinued. The aims of this study are to expand understanding of disease characteristics and treatment pattern of NF1-PN in China in a real-world setting and to evaluate real-world effectiveness and safety of selumetinib for Chinese pediatric patients with NF1-PN
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
NF1-PN patient demographics and disease characteristics at baseline and during selumetinib treatment
Timeframe: From baseline to 24 months after first dose of selumetinib
NF1-PN disease characteristics
Timeframe: From baseline to 24 months after first dose of selumetinib
Selumetinib treatment profile
Timeframe: From baseline to 24 months after first dose of selumetinib
Physician's qualitative assessment of disease status for clinically significant PN and overall disease status
Timeframe: From baseline to 24 months after first dose of selumetinib
NF1 disease status
Timeframe: From baseline to 24 months after first dose of selumetinib